Citius Oncology (NASDAQ:CTOR) Coverage Initiated by Analysts at Maxim Group

Maxim Group began coverage on shares of Citius Oncology (NASDAQ:CTOR) in a research report issued on Wednesday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $3.00 price target on the stock. Maxim Group’s price objective indicates a potential upside of 201.24% from the stock’s previous close.

Citius Oncology Stock Up 17.2 %

Shares of NASDAQ CTOR opened at $1.00 on Wednesday. The firm has a fifty day moving average of $1.21. Citius Oncology has a fifty-two week low of $0.85 and a fifty-two week high of $49.00.

Citius Oncology Company Profile

TenX Keane Acquisition Corp. is a blank check company. It formed for the purpose to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. TenX Keane Acquisition Corp. is based in New York.